Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Exelixis (EXEL) PT Raised to $30 at Oppenheimer

August 6, 2021 10:36 AM EDT

Oppenheimer analyst Silvan Tuerkcan raised the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $27.00) while maintaining an Outperform rating.

The analyst commented, "EXEL provided 2Q financial results featuring record Cabo sales of $284.2M with continued uptake of nivo + cabo in 1L RCC following FDA... More